MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results